Your session is about to expire
← Back to Search
Lenvatinib + Pembrolizumab for Liver Cancer
Study Summary
This trial will study if adding pembrolizumab to lenvatinib will help people with advanced hepatocellular carcinoma live longer without the cancer growing, and if it is safe.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 2 trial • 41 Patients • NCT02915783Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had major heart problems or strokes in the last year.I have had pneumonitis treated with steroids or have it now.I have been treated with specific immune therapy for cancer.I have been treated for an autoimmune disease in the last 2 years.I have a condition that affects how my body absorbs medication.I am 18 years or older.I have had significant coughing up of blood or tumor bleeding in the last 2 weeks.I have a severe fistula.My heart's pumping ability is below normal.I have another cancer besides skin cancer or in situ cancers that hasn't needed treatment in the last 3 years.I have received an organ or tissue transplant from another person.My liver cancer is at a stage where it can't be cured with surgery or local treatments.I had major liver surgery less than 4 weeks ago.I have active tuberculosis.I have an infection that needs treatment, but it's not HBV or HCV.I have had bleeding from varices in my esophagus or stomach in the past 6 months.I have an immune system disorder or have been on steroids or other immune-weakening medicines recently.My liver cancer diagnosis was confirmed through imaging or lab tests.My hepatitis B is under control.My liver is functioning well.I have or had cancer spread to my brain or spinal cord.I have not had chemotherapy for liver cancer or any cancer in the last 3 years.I am fully active or restricted in physically strenuous activity but can do light work.I have a serious wound or broken bone that is not healing.I had a minor surgery less than a week ago.I have a liver cancer lesion that can be measured.
- Group 1: lenvatinib plus pembrolizumab
- Group 2: lenvatinib plus placebo
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are some of the approved medical conditions that lenvatinib is used to manage?
"Lenvatinib has been shown to be effective in treating malignant neoplasms, unresectable melanoma, and microsatellite instability high."
Is this experiment still looking for test subjects?
"This particular trial is not currently recruiting patients. However, there are 2668 other trials involving carcinoma, hepatocellular patients and 1076 trials involving lenvatinib that are actively looking for participants."
What does the current research say about lenvatinib's efficacy?
"Currently, there are 1076 ongoing studies researching lenvatinib with 134 trials in Phase 3. The majority of the clinical trials for lenvatinib are running in Zaragoza, California, however, there are 37193 locations worldwide operating trials for lenvatinib."
What are the most common lenvatinib side effects that patients experience?
"Lenvatinib safety was rated a 3 by our Power team. This is due to the fact that it is a Phase 3 trial, which implies that there is both efficacy and safety data from multiple rounds of testing."
What is the patient limit for this research project?
"Unfortunately, this particular clinical trial is not currently taking on any more participants. However, there are 2668 other trials for patients with carcinoma, hepatocellular and 1076 trials for lenvatinib that are currently looking for patients."
Share this study with friends
Copy Link
Messenger